**Core tip:** *IL23R* gene plays important role in the development and influences the phenotype of inflammatory bowel diseases. We investigated the association of seven single nucleotide polymorphisms (SNPs) of *IL23R* gene with the clinical picture of ulcerative colitis (UC). Two SNPs were associated with greater colonic extension. At two SNPs, there was more frequently need for operations. Rs2201841 was found as a risk factor for the development of iron deficiency. Patients with rs10889677, therapy with azathioprine was more frequently necessary. Patients with rs10489629 SNP had lower risk for weight loss. This study demonstrated the influence of the investigated SNPs of *IL23R* on the phenotype of UC, confirming genetic association.

INTRODUCTION
============

Crohn\'s disease (CD) and ulcerative colitis (UC) represent the two most common forms of inflammatory bowel diseases (IBD). IBDs are complex diseases with suspected genetic and environmental etiology. Several IBD-associated genes were identified. Interleukin-23 receptor (*IL23R*) is one of those genetic factors found by genome-wide association studies (GWAS)\[[@B1]\]. Various studies suggest that the IL23-Th17 cell-axis plays an important role in the pathogenesis of IBDs.

*IL23R* is the human gene of the IL23-receptor located on chromosome 1p31\[[@B2]\]. IL23R is expressed by CD4+ T cells, monocytes/macrophages, and CD11c+ dendritic cells (DCs)\[[@B3]\]. IL23 is a pro-inflammatory cytokine belonging to the Interleukin 12-family\[[@B4]\]. It is a heterodimer consisting of subunit p19 (IL23A), and p40, a subunit of IL12B\[[@B5]\]. IL23 is mainly produced by activated macrophages and DCs\[[@B4]\].

Th17 cells differentiate from naive CD4+ Th cells under the influence of transforming growth factor beta (TGFβ) and IL6\[[@B6]\]. This can happen in a concentration-dependent manner. In a low concentration, TGFβ has synergistic effects with IL6 and IL21, which results in the induction of retinoid orphan nuclear receptor gamma t (Rorγt) and an increase of IL23, as well as promoting the differentiation into Th17 cells. In a high concentration, as well as in combination with IL2, TGFβ decreases the IL23-level, and raises the forkhead box protein transcription factor 3-level (Foxp3), which is a master regulator in the differentiation of regulatory T cells (Treg). This leads to the conclusion that there might exist a fluid balance between Th17 and Treg cells\[[@B7]\]. Pathogenic Th17 cells seem to play an important role in autoimmunity. Overexpression of Th17-associated cytokines in the bowel tissue of IBD patients was proven\[[@B8]\].

IL17, a pro-inflammatory cytokine produced by Th17 cells, is produced under the influence of IL23\[[@B6],[@B7]\]. It activates stromal and epithelial cells, which results in the excretion of cytokines and chemokines for chemotaxis of neutrophil leukocytes\[[@B9]\].

These pathways make IL23R a potential target in the treatment of various autoimmune inflammatory diseases. Ustekinumab and briakinumab, antibodies against the p40 subunit (IL12 and IL23) already demonstrated therapeutic efficiency in psoriasis, as well as in CD\[[@B10]-[@B12]\]. An IL12 antibody was able to induce remission in CD\[[@B13],[@B14]\].

Duerr et al\[[@B1]\] were the first who identified *IL23R* as a gene associated with IBDs. They were able to provide evidence for an association in non-Jewish UC population.

In a big German cohort Glas et al\[[@B4]\] investigated interactions of IBD genes and the influence of *IL23R* on the phenotype. All of observed *IL23R* gene variants, showed a strong association to CD and a weaker association to UC. Nevertheless, eight out of ten single nucleotide polymorphisms (SNPs) showed significant association with UC. The fact that these SNPs were either protective or susceptible in both CD and UC suggests similar disease-modifying effects. Rs7517847 was the SNP with the strongest association to, and the only independent risk factor of UC. The SNP with the strongest association to CD (rs1004819) was analyzed for phenotypic correlation. Though the TT homozygous carriers showed more frequently ileal involvement and stenosis, it did not reach significance. Rs7517847 did not show any specific influence on the phenotype of UC. There was no evidence for epistasis between the *IL23R*, and three other IBD genes *CARD15/NOD2*, *SLC22A4* and *SLC22A5*. Gene-gene interactions seemed to influence the phenotype but didn\'t reach statistical significance\[[@B4]\].

Hayatbakhsh et al\[[@B15]\] were able to connect the presence of rs7517847 in UC patients with two main clinical manifestations: blood in the stool and bowel movements. In a Jiangsu Han population the SNP rs17375018 with the G allele was correlated with mild activity in UC\[[@B16]\]. Recent studies also suggest the SNPs of *IL23R* to be a predictive factor of response to the therapy, *e.g*., non-response to mesalazine and corticosteroids as well as higher response rate for azathioprine and infliximab\[[@B17],[@B18]\].

The aim of our present study was to investigate the association of seven SNPs of *IL23R* (rs11209026, rs10889677, rs1004819, rs2201841, rs7517847, rs10489629, rs7530511) with the clinical picture of UC in Hungarian patients diagnosed with UC.

MATERIALS AND METHODS
=====================

Patients
--------

We examined 131 Hungarian patients of Caucasian origin (66 males, 65 females, mean age 55.4 ± 15.8 years) diagnosed with UC. The origin of the DNA samples was the central Biobank, governed by the University of Pecs, as part of the National Biobank Network of Hungary ([www.biobanks.hu](www.biobanks.hu)), which belongs to the pan-European Biobanking and Bio-molecular Resources Research Infrastructure preparatory phase project (<http://bbmri.eu/bbmri/>). The governance, maintenance and management principles of the Biobank had been approved by the National Scientific Research Ethics Committee (ETT TUKEB). Clinical data guidelines and regulations of the local Ethics Committee and Helsinki Declaration in 1975 were followed during collection and use of DNA samples. At blood collection patients gave their informed consent for the future use of their anonymized DNA.

The diagnosis of UC was based on the established clinical, endoscopic, radiological, and histopathological guidelines. Patients with indeterminate colitis were excluded from the study.

Genotyping
----------

DNA was extracted from peripheral blood leukocytes by routine salting out method. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were used to identify the alleles of the *IL23R* gene. The PCR amplifications were performed on MJ Research PTC-200 thermal cyclers (Bio-Rad LTD., Budapest, Hungary). Amplification included an initial denaturation step (96 °C for 2 min) followed by 35 cycles of denaturation (95 °C for 30 s), annealing for 30 s at 54 °C (rs1004819); 60 °C for 45 s (rs10889677 and rs7530511); 55 °C for 45 s (rs7517847, rs11209026 and rs10489629); 72 °C for 30 s (rs2201841), primer extension at 72 °C for 45 s and final extension at 72 °C for 5 min. Each polymerase chain reaction contained 200 μmol/L of each dNTP, 1 unit of Taq polymerase, 5 μL of reaction buffer (100 mmol/L Tris HCl, pH = 9.0; containing 500 mmol/L KCl, 15 mmol/L MgCl~2~), 0.2 μmol/L of each primer and 1 μL DNA to be amplified in a final volume of 50 μL. The amplicons were digested by allelespecific restriction endonucleases *TaaI* (rs1004819), *HpyF3I* (rs2201841), *MnlI* (rs10889677), *BseMII* (rs7517847), *HphI* (rs7530511), *Hpy188I* (rs11209026) and *SspI* (rs10489629). The amplicon contained an obligate cleavage site of the restriction enzyme for the suitable visual control of the efficacy of the digestion. The restriction fragments were separated by electrophoresis on 3% agarose gels containing ethidium bromide, and visualized by UV transillumination.

Statistical analysis
--------------------

The investigated phenotypic parameters included severity (age of manifestation, extension, frequency of relapse, blood in stool, bowel movements), complications (fever, weight loss, anemia, iron deficiency, hypoalbuminemia, need for operation), extraintestinal manifestation (in eyes, joints, skin), medication (aminosalicylate, azathioprine, corticosteroids), as well as familial cases of IBDs and colorectal cancer.

For the age of manifestation, three groups were formed analogous to the Montreal classification of CD (group 1: younger than 17 years, group 2: age between 17 and 40 years, group 3: older than 40 years). The extension of the disease along the colon was defined accordingly to the E-stages of the Montreal classification for UC (E1: involvement limited to the rectum, E2: involvement limited to distal of splenic flexure, E3: involvement extends to proximal to the splenic flexure)\[[@B19]\]. For analyzing the frequency of bowel movements, the patients were divided in three groups (group 1: one up to three a day, group 2: four up to ten a day, group 3: more than ten a day).

Data were examined for independence. Null hypothesis was formulated as follows: the phenotype of UC is independent of the genotype of *IL23R*.

2 × 3 or 3 × 3 contingency tables were created depending on the attribute. For characteristics that were tested for presence or lack of presence, 2 × 3 contingency tables were created. For characteristics divided in three subsets such as age of onset, Montreal-classification, frequency of relapse and bowel movements, 3 × 3 contingency tables were generated. Genotype was partitioned into wild type (Wt), heterozygous (Hz) and homozygous (Ho) susceptible SNP.

The distribution was tested in total (wild type + heterozygous + homozygous) as well as separated and regrouped. *χ*^2^-test was performed if the expected value was not lower than five in at least 80% of the cells. In any other case Fishers exact test was performed. For *χ*^2^-test SPSS Statistics 22.0 was used (SPSS Inc., Chicago, IL, United States). SPSS performs Fishers exact test for 2 × 2 contingency tables. Two other calculators were used, available on vassarstat.net and in-silico.net. Results were verified using Kruskal-Wallis-Test. Odds Ratios were determined only for 2 × 3 contingency tables.

*χ*^2^ test was accomplished using SPSS Statistics 22.0 (SPSS Inc., Chicago, IL, United States). *P* values below 0.05 were considered statistically significant. In this case null hypothesis was rejected.

RESULTS
=======

The frequencies of the genotypes and alleles are shown in Table [1](#T1){ref-type="table"}.

###### 

Genotypes of the investigated *IL23R* single nucleotide polymorphisms in Hungarian population *n* (%)

  **SNP**      **Genotype**   **UC**       **Allele**   **UC**
  ------------ -------------- ------------ ------------ ------------
  rs11209026   GG             109 (95.6)   G            223 (97.8)
  AG           5 (4.4)        A            5 (2.2)      
  AA           0 (0.0)                                  
  total        114                                      
  RAF          0.0219                                   
  rs10889677   CC             51 (45.5)    C            155 (69.2)
  AC           53 (47.3)      A            69 (30.8)    
  AA           8 (7.1)                                  
  total        112                                      
  RAF          0.308                                    
  rs1004819    GG             52 (40.3)    G            172 (66.7)
  AG           68 (52.7)      A            86 (33.3)    
  AA           9 (7.0)                                  
  total        129                                      
  RAF          0.333                                    
  rs2201841    TT             58 (45.0)    T            176 (68.2)
  CT           60 (46.5)      C            82 (31.8)    
  CC           11 (8.5)                                 
  Total        129                                      
  RAF          0.317                                    
  rs7517847    TT             40 (35.7)    T            136 (60.7)
  GT           56 (50.0)      G            88 (39.3)    
  GG           16 (14.3)                                
  Total        112                                      
  RAF          0.392                                    
  rs10489629   GG             44 (34.6)    G            155 (61.0)
  AG           67 (52.8)      A            99 (39.0)    
  AA           16 (12.6)                                
  Total        127                                      
  RAF          0.389                                    
  rs7530511    CC             94 (73.4)    C            220 (85.9)
  TC           32 (25.0)      T            36 (14.1)    
  TT           2 (1.6)                                  
  Total        128                                      
  RAF          0.140                                    

RAF: Risk allele frequency; SNP: Single nucleotide polymorphism; UC: Ulcerative colitis.

At the investigation of rs11209026, out of 114 subjects 109 (95.6%) carried the wild type (GG), while 5 (4.4%) were heterozygous (GA). The AA homozygous variant did not appear in this population. That is not surprising, considering a mean allele frequency of A = 0.0219. Regarding the low number of the SNP no significant results could have been expected.

For rs1004819, out of 129 subjects, 52 (40.3%) were wild type carriers (GG), while 68 (52.7%) carried the heterozygous (GA) and 9 (7%) the homozygous (AA) variant. For this polymorphisms no significant results were observed.

Out of 129 patients, 58 (40.0%) were carrier of the wild type (TT) of rs2201841, 60 (46.5%) carried the heterozygous (TC) and 11 (8.5%) the homozygous (CC) variant. Three characteristics reached level of significance: Montreal-Classification, appearance of iron deficiency and need for surgery (Figure [1](#F1){ref-type="fig"}). The Montreal-Classification and iron deficiency reached significance for the total distribution (Wt + Hz + Ho). Heterozygous carriers had significant higher risk to require surgery compared to the wild type (*P* = 0.0348, OR = 8.0). The distribution of the Montreal-Classification is shifted to greater extension for carriers of the heterozygous variant. Total distribution reached level of significance (*P* = 0.0084). This was verified by comparison of the obtained and expected values. The significance was mainly caused by the heterozygous TC variant (*P* = 0.0429).

![Distribution of the phenotype characteristics for the *IL23R* single nucleotide polymorphisms. A: Distribution of Montreal-classification (E1-3) for rs2201841; B: Summary of the occurrence and non-occurrence of iron deficiency for rs2201841; C: Representation of the number of operations regarding to rs2201841; D: Representation of stool frequency in three categories for rs7517847; E: Distribution of Montreal-classification (E1-3) on the alleles of rs10489629; F: Distribution of patients with and without weight loss to the alleles of rs10489629; G: Need to azathioprine therapy in respect to rs10889677; H: Representation of the number of operations regarding to rs10889677.](WJG-23-447-g001){#F1}

Carriers of the rs2201841 had significant higher risk for iron deficiency (*P* = 0.0299). When Hz and Ho SNPs were combined and compared with the Wt, no significance was observed (*P* = 0.7476). Statistically significance was found when Wt and Hz SNPs were merged and compared with the Ho variant (*P* = 0.0388, OR = 6.1837). Surgery was more frequently needed for heterozygous carriers of rs2201841 (*P* = 0.0348, OR = 8.0). The homozygous form seemed to have no influence on the need for operations.

Out of 112 patients, 40 (35.7%) carried the wild type (TT), 56 (50%) the heterozygous (TG) and 16 (14.3%) the homozygous (GG) rs7517847 SNP. Frequency of bowel movements was significant (*P* = 0.0078). If instead of three (\< 4, 4-10, \> 10) just two groups were used (\< 3 and \> 3 defecations per day), the distribution was still significant (*P* = 0.0358). If homozygous and heterozygous SNP were added together and compared to the wild type, no significant difference was found (*P* = 0.0634). Significance was caused by the heterozygous variant compared to the wild type (*P* = 0.0050). The rs7517847 seems to have a protective character and prevent its carrier from severe bowel movements.

Analyzing the rs7530511 SNP, 94 (73.4%) of 129 patients carried the wild type (CC), 32 (25.0%) the heterozygous (CT) and 2 (1.6%) the homozygous (TT) variant. No significant results were observed.

Out of 127 patients 44 (34.6%) carried the wild type (GG), 67 (52.8%) the heterozygous (GA) and 16 (12.6%) the homozygous (AA) variant of rs10489629 SNP. Total distribution (Wt + Hz + Ho) of the Montreal-Classification was significant (*P* = 0.0405). Carrying the Hz and Ho SNP alone didn\'t reach level of significance. Carriers of the heterozygous variant had a higher risk for an extended disease (*P* = 0.0284). For weight loss significance was observed (*P* = 0.035). If wild type was compared with heterozygous and homozygous SNP together (Hz + Ho) significance was reached (*P* = 0.0169, OR = 0.3394). The homozygous variant showed significance (*P* = 0.0457, OR = 0.1244). Patients who carried the heterozygous susceptible SNP had numerous but statistically not significant lower risk of weight loss (*P* = 0.0652).

In the case of rs10889677 SNP, out of 112 patients, 51 (45.5%) carried the wild type (CC), 53 (47.3%) the heterozygous (CA) and 8 (7.1%) the homozygous (AA) variant. Carriers of the susceptible SNP needed more frequently azathioprine treatment (*P* = 0.0285). If wild type was compared with the heterozygous and homozygous SNP, level of significance was found (*P* = 0.0136, OR = 5.8732). The heterozygous variant also leads to a higher risk for need for surgery (*P* = 0.0347, OR = 8.0).

Summarized four out of seven SNPs had a statistically significant influence on the phenotype of UC. The results are shown in Table [2](#T2){ref-type="table"}.

###### 

*IL23R* single nucleotide polymorphisms with statistically significant influence on the clinical picture of ulcerative colitis

  **SNP**                   **Wt *vs* Hz**   **Wt *vs* Ho**   **Wt *vs* Hz + Ho**   **Wt + Hz *vs* Ho**   **Total distribution**
  ------------------------- ---------------- ---------------- --------------------- --------------------- ------------------------
  rs2201841                                                                                               
  Montreal-classification   0.0429^a^        0.2270           0.1921                0.0217^a^             0.0084^a^
  Iron deficiency           0.1892           0.1108           0.7476                0.0388^a^             0.0299^a^
  Need for operation        0.0348^a^        1.0000           0.0766                0.6017                0.0564
  rs7517847                                                                                               
  Bowel movements           0.0050^a^        0.8183           0.0634                0.2979                0.0078^a^
  rs10489629                                                                                              
  Montreal classification   0.1017           0.3906           0.4445                0.1170                0.0405^a^
  Weight loss               0.0652           0.0457^a^        0.0169^a^             0.1191                0.0350^a^
  rs10889677                                                                                              
  Azathioprine              0.0116^a^        0.3407           0.0136^a^             0.6113                0.0285^a^
  Need for operation        0.0347^a^        0.8491           0.0746                0.6153                0.0595

Indicates significant difference (^a^*P* \< 0.05). Hz: Heterozygous; Ho: Homozygous; Wt: Wild type; Total distribution: Wt + Hz + Ho; SNP: Single nucleotide polymorphism.

The rs2201841 showed higher stage of extension along the colon (*P* = 0.0084). The CC homozygous carriers had a higher risk for iron deficiency (*P* = 0.0388, OR = 6.183). Patients with the heterozygous genotype needed more often operation (*P* = 0.0348, OR = 8.0).

Patients with the rs7517847 GT heterozygous variant suffered less from bowel movements (*P* = 0.005).

The rs10489629 SNP in heterozygous form was connected to greater colonic extension (*P* = 0.0405). Both the heterozygous and homozygous from this variant were associated with lower risk of weight loss (*P* = 0.0169, OR = 0.3394). In case of rs10889677, therapy with azathioprine was more often necessary for patients carrying the heterozygous and the homozygous SNP (*P* = 0.0116, OR = 6.1707). Heterozygous carriers showed higher risk for the need of operations (*P* = 0.0347, OR = 8.0).

The reason for the statistical significance only to appear for the heterozygous genotype in some cases can be attributable to low numbers of homozygous carriers.

The variants rs11209026, rs1004819, and rs7530511 had no statistical significant influence on the phenotype of UC.

DISCUSSION
==========

Several recent studies suggest *IL23R* to be a suspect in the pathogenesis of diverse autoimmune diseases such as IBDs\[[@B1],[@B4],[@B20]-[@B25]\], psoriasis\[[@B11],[@B22],[@B26]\], Graves disease\[[@B27]\], ankylosing spondylitis\[[@B28],[@B29]\], and rheumatoid arthritis\[[@B26],[@B29]-[@B31]\]. Previous investigations in Hungarian populations verified *IL23R* to play a role in the development of UC\[[@B25],[@B32]\]. The present study demonstrated the correlation between the SNPs of *IL23R*, and the phenotype of UC.

Two of the susceptible SNPs for the development of UC (rs2201841, rs10889677) seem to shift the clinical picture from mild into more severe. The rs10889677 was associated with azathioprine-therapy, suggesting the patients to be refractory to 5-aminosalicylic-acid (5-ASA). These results are analogous to the findings of Cravo et al\[[@B18]\]. Interestingly one risk-polymorphism (rs10489629) had risk-conferring (greater extension), and protective features (lower risk of weight loss). The reason for the protective and harming character of rs10489629 remains unclear. A possible connection could be a more frequent need for steroids because of the greater extension of the disease along the colon, leading to a lower risk for weight loss. This study did investigate the need for corticosteroids but not the administration frequency. No significant higher need for steroids could been shown. The rs7517847 variant showed a protective character (less bowel movements). Rs7517847 has shown to protect the individual from acquiring the disease\[[@B4]\], assuming a general protective character of this polymorphism.

An Iranian study (Hayatbakhsh et al\[[@B15]\], 2012) demonstrated the protective influence of rs7517847 on bowel movements, and blood in stool, the two important features of UC. We were partly able to reproduce these results for the examined Hungarian population. The rs1004819 showed no influence on these characteristics, neither in the Iranian nor the present study. Chinese research detected similar results suggesting the rs17375018 SNP to have a protective character\[[@B20]\]. There are studies that suggest *IL23R* to be a risk factor for the development of extraintestinal manifestations\[[@B18]\]. This was not reproducible in our study with Hungarian UC patients.

The data of the present study are in contrast to the results of Duerr et al\[[@B1]\] and Glas et al\[[@B4]\], who did find an association between *IL23R* and inflammatory bowel diseases but no influence on the phenotype of ulcerative colitis.

More studies are necessary to clarify the exact role of *IL23R* in the development of IBDs, as well as other autoimmune diseases, to improve the knowledge about their pathogenesis and pathophysiology. This may allow individual risk stratification, individual pharmacotherapy, and new approaches for medication with targeted therapy.
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COMMENTS
========

Background
----------

Inflammatory bowel diseases (IBD) are complex diseases with suspected genetic and environmental etiology. Interleukin-23 receptor (*IL23R*) is one of those genetic factors found by genome-wide association studies. IL23R is expressed by CD4+ T cells, monocytes/macrophages, and CD11c+ dendritic cells. IL23 is a pro-inflammatory cytokine which has potential target in the treatment of various autoimmune inflammatory diseases. Duerr et al were the first who identified *IL23R* as a gene associated with IBDs. They were able to provide evidence for an association in non-Jewish ulcerative colitis (UC) population. In a big German cohort Glas et al (2007) investigated interactions of IBD genes and the influence of *IL23R* on the phenotype. Eight out of ten single nucleotide polymorphisms (SNPs) showed significant association with UC. The fact that these SNPs were either protective or susceptible in both Crohn\'s disease and UC suggests similar disease-modifying effects. Recent studies also suggest the SNPs of *IL23R* to be a predictive factor of response to the therapy, *e.g*., non-response to mesalazine and corticosteroids as well as higher response rate for azathioprine and infliximab.

Research frontiers
------------------

Previous investigations in Hungarian populations verified *IL23R* to play a role in the development of UC. The present study demonstrated the correlation between the SNPs of *IL23R*, and the phenotype of UC.

Innovations and breakthroughs
-----------------------------

Two of the susceptible SNPs for the development of UC (rs2201841, rs10889677) seem to shift the clinical picture from mild into more severe. The rs10889677 was associated with azathioprine-therapy, suggesting the patients to be refractory to 5-aminosalicylic-acid. The rs7517847 variant showed a protective character (less bowel movements). Rs7517847 has shown to protect the individual from acquiring the disease, assuming a general protective character of this polymorphism.

Applications
------------

These results may allow individual risk stratification, individual pharmacotherapy, and new approaches for medication with targeted therapy. However, more studies are necessary to clarify the exact role of *IL23R* in the development of IBDs.

Peer-review
-----------

The study is well conducted, the results are interesting but, as the number of patients is not very high, the data should be validated in another cohort in a future study.
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